Skip to main content
SpringerLink
Log in
Book cover

Management des Ovarialkarzinoms pp 325–338Cite as

Versorgungsstruktur, Qualitätssicherung und klinische Studien beim invasiven Ovarialkarzinom in Deutschland — Aktionsprogramm QS-OVAR der AGO und Aktivitäten der AGO-Studiengruppe

  • Chapter

Part of the book series: Onkologie aktuell ((ONKAKTUELL))

Auszug

Das Ovarialkarzinom ist unverändert die führende Todesursache bei den gynäkologischen Tumoren. Das Lebenszeitrisiko variiert zwischen 1,1 und 1,6 in Europa und den USA (Parkin et al. 2002). Unter dem ICD-Code für maligne Ovarialtumoren verbergen sich so unterschiedliche Entitäten wie Keimzelltumoren, Stromazelltumoren, Sarkome und epitheliale Tumoren. Legt man die amerikanischen Daten zugrunde, so sind 78,7% der malignen Ovarialtumoren invasive Karzinome (Goodmann u. Howe 2003). Dies entspräche gemäß den Daten aus dem Robert-Koch-Institut einer jährlichen Inzidenz von etwa 6000–8000 Neudiagnosen eines epithelialen Ovarialkarzinoms für Deutschland.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   44.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Antman K., Amato D, Wood W et al.: Selection bias in clincal trials. J Clin Oncol 3: 1142–1147, 1985.

    PubMed  CAS  Google Scholar 

  • Arbeitsgemeinschaft Gynäkologische Onkologie Organkommission OVAR: Ovarialkarzinom State of the Art 2003, ISBN 3-00-011911-6, 2003.

    Google Scholar 

  • Bauknecht T, Breitbach GP, Bois A du et al.: Maligne Ovarialtumoren. In: Deutsche Krebsgesellschaft e. V., Qualitätssicherung in der On kologie, kurzgefasste interdisziplinäre Leitlinien 2000. München, Zuckschwerdt, 2000, S 301–318

    Google Scholar 

  • Belau A, Pfisterer J, Wimberger P, Kurzeder C, du Bois A, Sehouli J, Loibl S, Burchardi N, Vergote I, Wagner U (2007) Randomized, multicenter, 2-dose-level, open-label, phase lla study with the intraperitoneally infused trifunctional bispecific antibody catumaxomab (anti-EpCAM x anti-CD3) to select the better dose level in patinum refractory epithelial ovarian cancer patients, J Clin Oncol 25, 18S: 5556

    Google Scholar 

  • Berrino F, Capocaccia R, Esteve J et al. (eds.): Survival of cancer patients in Europe: the EUROCARE-2 study. IARC Scientific Publications No. 151, Lyon, 1999.

    Google Scholar 

  • Berrino F, Capocaccia R, Coleman MP et al. (eds.): Survival of cancer patients in Europe: the EUROCARE-3 study. Ann Oncol 14 (Suppl 3): v100, 2003

    Google Scholar 

  • Boros L, Chuang C, Butler FO, Bennett JM: Leukemia in Rochester (NY). A 17-year experience with an analysis of the role of Cooperative Group (ECOG) participation. Cancer 56: 2161–2169, 1985

    Article  PubMed  CAS  Google Scholar 

  • Braunholtz DA, Edwards SJL, Lilford RJ: Are randomized clinical trials good for us (in short term)? Evidence for a »trial effect«. J Clin Epidemiol 54: 217–224, 2001

    Article  PubMed  CAS  Google Scholar 

  • Burger JA, Arance A, Ashcroft L et al.: Identical chemotherapy schedules given on and off trial protocol in small cell lung cancer reponse and survival results. Br J Cancer 87: 562–566, 2002

    Article  Google Scholar 

  • Cottin V, Arpin D, Lasset C et al.: Small-cell lung cancer: Patients included in clinical trials are not representative of the patient population as a whole. Ann Oncol 10: 809–815 1999.

    Article  PubMed  CAS  Google Scholar 

  • Cress RD, O’Malley CD, Leiserowitz GS et al: Patterns of chemotherapy use for women with ovarian cancer: a population-based study. J Clin Oncol 21: 1530–1535, 2003

    Article  PubMed  Google Scholar 

  • Davis S, Wright PW, Schulman SF et al.: Participants in prospective, randomized clinical trials for resected non-small cell lung cancer have improved survival compared with nonparticipants in such trials. Cancer 56: 1710–1718, 1985

    Article  PubMed  CAS  Google Scholar 

  • du Dois A, Pfisterer J, Kellermann L, et al.: Die Therapie, des fortgeschrittenen Ovarialkarzinoms in Deutschland: Welchen Einfluss hat die Teilnahme an klinischen Studien? Geburtsch. u. Frauenheilked 61: 863–871, 2001a

    Article  Google Scholar 

  • du Bois A, Pfisterer J, Kellermann L: Die Therapie des fortgeschrittenen Ovarialkarzinoms in Deutschland: Ergebnisse einer Umfrage der Organkommission OVAR der Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) in der Deutschen Krebsgesellschaft. Gynäkologe 34: 1029–1040, 2001b

    Article  Google Scholar 

  • du Bois A, Quinn M, Thigpen T et al.: 2004 Consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004), Ann Oncol 16 (Suppl. 8): viii7–viii12, 2005a

    Google Scholar 

  • du Bois A, Rochon J, Lamparter C et al: Pattern of care and impact of participation in clinical trials on outcome in ovarian oancer. Int J Gynecol Cancer 15: 183–191, 2005b

    Article  PubMed  Google Scholar 

  • du Bois A, Rochon J, Lamparter C, Pfisterer J: Das Qualitätssicherungsprogramm der AGO Organkommission OVAR (QS-OVAR): Ver sorgungsstruktur und Realität in Deutschland 2001. Zentralbl Gynakol 127: 9–17, 2005c

    Article  PubMed  Google Scholar 

  • du Bois A, Rochon J, Lamparter C, Pfisterer: Welchen Einfluss haben Klinikmerkmale auf die Prognose des Ovarialkarzinoms in Deutschland? Zentralbl Gynakol 127: 18–30, 2005d

    Article  PubMed  Google Scholar 

  • du Bois A, Rochon J, Lamparter C, Pfisterer J: Ovarialkarzinom — Versorgungsstruktur und-qualität in Deutschland 2001–2004, Frauenarzt 7/2005: 560–567, 2005e

    Google Scholar 

  • Eisenkop SM, Spirtos NM: What are current surgical objectives, strategies, and technical capabilities of gynecologic oncologists treating advanced epithelial ovarian cancer? Gynecol Oncol 82: 489–497, 2001

    Article  PubMed  CAS  Google Scholar 

  • Gnant M on behalf of the Austrian Breast & Colorectal Cancer Study Group: Impact of participation in randomized clinical trials on survival of women with early stage breast cancer. Proc Am Soc Clin Oncol 19: 74a, 2000 (Abstr)

    Google Scholar 

  • Goodmann MT, Howe HL: Descriptive epidemiology of ovarian cancer in the United States, 1992–1997. Cancer 97 (Suppl): 2615–2630, 2003

    Google Scholar 

  • Harlan LC, Clegg LX, Trimble EL: Trends in surgery and chemotherapy for women diagnosed with ovarian cancer in the United States. J Clin Oncol 21:3488–3494, 2003

    Article  PubMed  Google Scholar 

  • Heintz APM, Odincino F, Maisonneuve P et al. Carcinoma of the ovary. In: Pecorelli S (ed) FIGO Annual report on the results of treatment in gynaecological cancer. J Epidemiology Biostatistics 6 107–138, 2001

    Google Scholar 

  • Hjorth M, Holmberg E, Rödjer S, Westin J: Impact of active and passive exclusions on the results of a clinical trial in multiple myeloma. Br J Haematol 80: 55–61, 1992

    Article  PubMed  CAS  Google Scholar 

  • Karjalainen S, Palva I: Do treatment protocols improve end results? A study of survival of patients with multiple myeloma in Finland. BMJ 299: 1069–1989, 1989

    Article  PubMed  CAS  Google Scholar 

  • Lin PS, Gershenson DM, Bevers M, Lucas K, Burke TW, Silva EG: The current status of surgical staging of ovarian serous borderline tumors. Cancer 85: 905–911, 1999

    Article  PubMed  CAS  Google Scholar 

  • McGowan L, Lesher LP, Norris HJ et al.: Misstaging of ovarian cancer. Obstet Gynecol 65: 568–572, 1985

    PubMed  CAS  Google Scholar 

  • Meier W, du Bois A, Reuss A, Kuhn W, Gropp M, Pfisterer J, Kimmig R, Olbricht S, Wagner U, Richter B, Moebus V (2004) Topotecan versus treosulfan in early recurrent ovarian cancer after primary platinum/paditaxel chemotherapy. A prospective randomized phase III trial of the AGO Ovarian Cancer Study Group, Int J Gynecol Cancer 2004, 14 (Suppl 1), 2

    Google Scholar 

  • Munoz KA, Harlan LC, Trimble EL: Patterns of care for women with ovarian cancer in the United States. J Clin Oncol 15: 3408–3415, 1997

    PubMed  CAS  Google Scholar 

  • O’Malley CD, Cress RD, Campleman SL, Leiserowitz GS: Survival of California women with epithelial ovarian cancer, 1994–1996: A population-based study. Gynecol Oncol 91:608–615, 2003

    Article  PubMed  Google Scholar 

  • Obermair A, Sevelda P, Oberaigner W, Marth C: Wie gut ist die Behandlung des Ovarialkarzinoms in Österreich? Frauenarzt 44: 732–736, 2003

    Google Scholar 

  • Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB (eds.): Cancer incidence infive continents. Vol. VIII, IARC Scientific Publications No. 155, Lyon, France, 2002

    Google Scholar 

  • Peppercorn JM, Weeks JC, Cook EF et al.: Comparison of outcomes in cancer patients treated within and outside clinical trials: conceptual framework and structured review. Lancet 363: 263–270, 2004

    Article  PubMed  Google Scholar 

  • Rahman ZU, Frye DK, Buzdar AU et al.: Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemotherapy in patients with metastatic breast cancer. J Clin Oncol 15:3171–3177, 1997

    PubMed  CAS  Google Scholar 

  • Tingulstad S, Skjeldestad FE, Halvorsen TB, Hagen B: Survival and prognostic factors in patients with ovarian cancer. Obstet Gynecol 101: 885–891, 2003

    Article  PubMed  Google Scholar 

  • Wagner HP, Dingeldein-Bettler I, Berchthold W et al.: Childhood NHL in Swizerland: Incidence and survival of 120 study and 42 non-study patients. Med Pediatr Oncol 24: 281–286, 1995

    Article  PubMed  CAS  Google Scholar 

  • Ward LC, Fielding JWL, Dunn JA et al.: The selection of cases for randomised, trials: a registry survey of concurrent trial and non-trial patients. Br J Cancer 66: 943–930, 1992

    PubMed  CAS  Google Scholar 

  • Winger MJ, Macdonald DR, Schold C, Cairncross JG: Selection bias in clinical trials of anaplastic glioma. Ann Neurol 26: 531–534, 1989

    Article  PubMed  CAS  Google Scholar 

  • Wolfe CDA, Tilling K, Raju KS: Management and survival of ovarian cancer patients in South East England. Eur J Cancer 33: 1835–1840, 1997

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Gynäkologie und Gyn. Onkologie, Dr.-Horst-Schmidt-Kliniken, Ludwig-Erhard-Straße 100, 65199, Wiesbaden

    Prof. Dr. med. A. du Bois

  2. Zentrum für Klinische Studien, Klinikum der Universität Regensburg, Franz-Josef-Strauß-Allee 11, 93053, Regensburg

    J. Rochon

  3. MMF Marktforschung GmbH, Appelsiepen 137, 58313, Herdecke

    Dr. C. Lamparter

  4. AGO-Studiengruppe, Kaiser-Friedrich-Ring 71, 65185, Wiesbaden

    G. Elser

  5. Klinik für Gunäkologie und Geburtshilfe Campus Kiel, Universitätsklinikum Schleswig-Holstein, Michaelisstr. 16, 24105, Kiel

    Prof. Dr. med. J. Pfisterer

Authors
  1. Prof. Dr. med. A. du Bois
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. Rochon
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dr. C. Lamparter
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. G. Elser
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Prof. Dr. med. J. Pfisterer
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Springer Medizin Verlag Heidelberg

About this chapter

Cite this chapter

du Bois, A., Rochon, J., Lamparter, C., Elser, G., Pfisterer, J. (2009). Versorgungsstruktur, Qualitätssicherung und klinische Studien beim invasiven Ovarialkarzinom in Deutschland — Aktionsprogramm QS-OVAR der AGO und Aktivitäten der AGO-Studiengruppe. In: Management des Ovarialkarzinoms. Onkologie aktuell. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-68857-0_22

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-68857-0_22

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-41987-7

  • Online ISBN: 978-3-540-68857-0

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation